HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, has begun dosing healthy volunteers in a Phase I clinical trial of GlycoPEG-GCSF, a long-acting, GlycoPEGylated™ granulocyte colony stimulating factor for the treatment of neutropenia. The trial, which is being conducted in Western Europe, will evaluate the safety, pharmacokinetics and pharmacodynamics of GlycoPEG-GCSF versus Neulasta® in approximately 60 healthy volunteers. The Phase I trial is designed as a single-blind, randomized, ascending-dose study that will evaluate subcutaneous administration of GlycoPEG-GCSF.
